Novel pharmacological approaches in the treatment of psoriasis
Authors:
- 10 December 2004
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 19 (1) , 1-20
Abstract
Progress in the understanding of psoriasis as a T‐cell mediated inflammatory disease has led to the development of new immunomodulatory therapies. Currently the main focus is on the so‐called biologics (or biological agents), including fusion proteins, monoclonal antibodies, cytokines and selective receptors. They mainly target single steps in the complex cascade of humoral and cellular inflammatory immunomechanisms that finally lead to the accelerated growth of epidermal and vascular cells in the psoriatic lesions. The most promising and advanced biological agents are discussed along with their influence on the critical pathophysiological steps in psoriasis, including depletion of T cells, blockade of initial T‐cell activation and T‐cell receptor (TCR) stimulation, blockade of costimulatory signals and T‐cell proliferative signals as well as restoration of the T helper type 1 (Th1)/Th2 balance by diminishing type 1 cytokines and administration of type 2 cytokines. In addition to the biological agents, further development of ‘classical’ dermatological therapies, such as retinoids, or the discovery of new indications for non‐dermatological agents contribute to the novel pharmacological approaches in the treatment of psoriasis.Keywords
This publication has 184 references indexed in Scilit:
- Recombinantly Engineered Human Proteins: Transforming the Treatment of PsoriasisClinical Immunology, 2002
- The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretinBritish Journal of Dermatology, 1998
- LiarozoleDrugs & Aging, 1996
- Distinct antigen-induced cytokine pattern upon stimulation with antibody-complexed antigen consistent with a Th1 → Th2-shiftResearch in Virology, 1996
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992
- Peptide T improves psoriasis when infused into lesions in nanogram amountsJournal of the American Academy of Dermatology, 1991
- Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosisTubercle, 1990
- Mycophenolic acid for psoriasisJournal of the American Academy of Dermatology, 1987
- The major internal protein, p27, of a retrovirus-like particle is expressed in blood lymphocytes from psoriatic patientsArchives of Virology, 1985
- Efficacy of mycophenolic acid for the treatment of psoriasisJournal of the American Academy of Dermatology, 1979